PCV2 vaccine approved for pregnant sows
PCV2 can have a devastating impact on pig health, as well as economic losses for farmers.
A vaccine to protect against porcine circovirus type 2 (PCV2) has now been approved for use in pregnant and lactating sows.
The European Medicines Agency has authorised this use of the Ingelvac CircoFLEX, which was developed by Boehringer Ingelheim.
According to the head of the pharma company, George Heidgerken, this is the first PCV2 vaccine to be licensed in the EU for the protection of both piglets and sows.
PCV2 can have a devastating impact on pig health, as well as economic losses for farmers. Infection may lead to wasting, paleness of the skin, dyspnea or diarrhoea in piglets and, in breeding sows, can result in reproductive losses.
In both piglets and sows, the virus can also cause subclinical infections.
According to Boehringer, Ingelvac CircoFLEX reduces mortality, clinical signs and lesions associated with PCV2.
In addition, the company says studies have shown vaccinating sows has 'significant positive effects' on reproductive performance and the number of piglets born alive and weaned.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
